The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...
The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy. The Food and Drug ...
NEW ORLEANS -- Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, ...
AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD). Vraylar is presently approved for treating ...
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results